Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...

Virginia Tech scientists found that age-related memory loss stems from molecular changes in the brain. Memory decline might not be just a natural part of aging. Researchers at Virginia Tech have ...

A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the ...

As we look ahead in 2025, the pace of discovery in genetics continues to accelerate, marking the third decade of the 21st century with remarkable ...

The apparel industry accounts for 10% of greenhouse gas emissions. Biotechs are working on reengineering natural products to make more sustainable textiles, which are gaining traction.

They're exploring its use for groundbreaking treatments for cancer and autoimmune disease, as well as for gene-editing ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Scientists are on the brink of even preventing some diseases — not just treating them — at the sperm, egg and early embryo ...

New scientific article warns of loss of consumer trust unless proper analysis is done. Report: Claire Robinson ...